Purple Biotech Ltd.

Regulatory Filings • Apr 1, 2020

_________ false

����� ����� ��"�	2 379
KITOV PHARMA LTD
Corporation no: 520031238	10994
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C001 ( Public )		Reported via MAGNA:	31/03/2020
	www.isa.gov.il			www.tase.co.il				Reference:	2020-02-034068	Time of broadcast: 22:59 22:56:35

Complementary report for a report sent on date 24/03/2020 whose reference number was 2020-02-025273

Main details added/ completed:

This Amendment No. 1 (this �Amendment�) to our annual report on Form 20-F for the fiscal year ended December 31, 2019 (the �Form 20-F�), filed on March 23, 2020 (the �Original Filing Date�), is being filed solely to submit Exhibits 4.23, 4.24, 4.25. 4.26 and 4.27 with the redaction of confidential information in material contracts, as well as to submit revised share ownership of officers and major shareholders in order to reflect recent Section 13 filings by certain shareholders. Additionally, in connection with the filing of this Amendment, the Company is including certifications of the Company�s Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.1350) as no financial statements are being filed with this Amendment. Except for the aforesaid Exhibits and revised share ownership disclosures, this Amendment does not amend any other information set forth in the Form 20-F. This Amendment speaks as of the Original Filing Date, and other than as explicitly set forth herein, does not reflect any events that may have occurred subsequent to the Original Filing Date, and does not modify or update in any way any disclosures made in the Form 20-F.

---

Report of Periodic or Interim ReportRegulation 3 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onAmendment No. 1 (this �Amendment�) to our annual report on Form 20-F for the fiscal year ended December 31, 2019 (the �Form 20-F�), filed on March 23, 2020.

f20f2019a1_kitovpharmaEDGAR5_Bannerless_isa.pdf

Link to filing on foreign stock exchange (optional): https://www.sec.gov/cgi-bin/browse-edgar?company=kitov&owner=exclude&action=getcompany

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
2020-02-025273
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 18/02/2020
Address: Menachem Begin St, Azrieli Towers Round Tower 132 , Tel Aviv 6701101   , Israel Tel: 03-9333121 , Fax: 03-5097196
E-mail address: info@kitovpharma.com   Company site: www.kitovpharma.com
Previous names of reporting entity: KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory: BEN-TZVI ABRAHAM SHLOMO Position of Signatory in the reporting corporation: Lawyer/ Legal Counsel Name of Employer Company: ABZ Law Office
Address: Yad Harutzim 15 , Jerusalem 9342152 Telephone: 079-5722070 Facsimile: 079-5722206 E-mail: abz@abz-law.com 1
Israel